Patents by Inventor Karin Kolmodin
Karin Kolmodin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110319426Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: September 6, 2011Publication date: December 29, 2011Applicant: ASTRAZENECA ABInventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
-
Patent number: 8030500Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: GrantFiled: November 13, 2009Date of Patent: October 4, 2011Assignee: AstraZeneca ABInventors: Jörg Holenz, Sofia Karlström, Karin Kolmodin, Johan Lindström, Laszlo Rakos, Didier Rotticci, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg
-
Publication number: 20110059992Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: November 11, 2010Publication date: March 10, 2011Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LTD.Inventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jörg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Öhberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Patent number: 7855213Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: GrantFiled: June 13, 2007Date of Patent: December 21, 2010Assignees: AstraZeneca AB, Astex Therapeutics Ltd.Inventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jörg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Öhberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Publication number: 20100298340Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: April 12, 2007Publication date: November 25, 2010Applicants: AstraZeneca AB, Astex Therapeutics Ltd.Inventors: Stefan Berg, Karin Kolmodin
-
Publication number: 20100125087Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: AstraZeneca ABInventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Laszlo RAKOS, Peter SODERMAN, Britt-Marie SWAHN, Stefan VON BERG, Fredrik VON KIESERITZKY
-
Publication number: 20100125081Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: ASTRAZENECA ABInventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SODERMAN, Marie SUNDSTROM, Britt-Marie SWAHN, Stefan VON BERG
-
Publication number: 20100125082Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: ASTRAZENECA ABInventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
-
Publication number: 20090233930Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: November 20, 2006Publication date: September 17, 2009Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITEDInventors: Stefan Berg, Jeremy Burrows, Gianni Chessari, Miles Stuart Congreve, Johan Hedstrom, Sven Hellberg, Katharina Hogdin, Jacob Kihlstrom, Karin Kolmodin, Johan Lindstrom, Christopher Murray, Sahil Patel
-
Publication number: 20090233943Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: May 14, 2008Publication date: September 17, 2009Applicants: Astex Therapeutics Limited, AstraZeneca ABInventors: Jeremy Nicholas Burrows, Sven Hellberg, Katharina Hogdin, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Can Slivo
-
Publication number: 20090023762Abstract: This invention relates to novel compounds having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel en compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: December 18, 2006Publication date: January 22, 2009Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITEDInventors: Stefan Berg, Jeremy Burrows, Sven Hellberg, Katharina Hogdin, Karin Kolmodin
-
Publication number: 20080293718Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: November 20, 2006Publication date: November 27, 2008Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITEDInventors: Stefan Berg, Jeremy Burrows, Gianni Chessari, Miles Stuart Congreve, Johan Hedstrom, Sven Hellberg, Katharina Hogdin, Jacob Kihlstrom, Karin Kolmodin, Johan Lindstrom, Christopher Murray, Sahil Patel
-
Publication number: 20080287460Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: May 14, 2008Publication date: November 20, 2008Applicants: Astex Therapeutics Limited, AstraZeneca ABInventors: Jeremy Nicholas Burrows, Sven Hellberg, Katharina Hogdin, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Can Slivo
-
Publication number: 20080214577Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 11, 2007Publication date: September 4, 2008Applicants: AstraZeneca AB, Astex Therapeutics LtdInventors: Stefan Berg, Jorg Holenz, Katharina Hogdin, Karin Kolmodin, Niklas Plobeck, Didier Rotticci, Fernando Sehgelmeble, Maria Wirstam
-
Publication number: 20080171771Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 13, 2007Publication date: July 17, 2008Applicants: AstraZeneca AB, Astex Therapeutics LtdInventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jorg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Ohberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Publication number: 20080161269Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: December 19, 2007Publication date: July 3, 2008Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITEDInventors: Stefan Berg, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Jan-Erik Nystrom, Fernando Sehgelmeble, Peter Soderman
-
Publication number: 20080058349Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 11, 2007Publication date: March 6, 2008Applicants: Astrazeneca AB, Astex Therapeutics LtdInventors: Stefan Berg, Jorg Holenz, Katharina Hogdin, Jacob Kihlstrom, Karin Kolmodin, Johan Lindstrom, Niklas Plobeck, Didier Rotticci, Fernando Sehgelmeble, Maria Wirstam
-
Publication number: 20070299087Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 11, 2007Publication date: December 27, 2007Applicants: AstraZeneca AB, Astex Therapeutics Ltd.Inventors: Stefan Berg, Jorg Holenz, Katharina Hogdin, Karin Kolmodin, Niklas Plobeck, Didier Rotticci, Fernando Sehgelmeble